92
Participants
Start Date
November 12, 2024
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
ZP9830
Participants will receive 1 single dose of ZP9830 given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm). Dose level will depend on the cohort.
Placebo
Participants will receive 1 single dose of placebo given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm). Volume will be matching the active treatment
RECRUITING
Centre for Human Drug Research, Leiden
Lead Sponsor
Zealand Pharma
INDUSTRY